Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema

Trial Profile

A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2018

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Sponsors Mylan
  • Most Recent Events

    • 21 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 25 Jul 2018 Status changed from planning to not yet recruiting.
    • 08 May 2018 According to a Momenta Pharmaceuticals media release, the company has announced IND acceptance by the FDA in January 2018, to start the trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top